Scarica l'app Stockscreener
0.26
3.38%
-0.0091
Dopo l'orario di chiusura:
.27
0.01
+3.85%
Precedente Chiudi:
$0.2691
Aprire:
$0.2765
Volume 24 ore:
3.50M
Relative Volume:
0.71
Capitalizzazione di mercato:
$19.57M
Reddito:
-
Utile/perdita netta:
$-31.88M
Rapporto P/E:
-0.3467
EPS:
-0.75
Flusso di cassa netto:
$-25.20M
1 W Prestazione:
-4.38%
1M Prestazione:
+3.59%
6M Prestazione:
-48.01%
1 anno Prestazione:
-76.15%
Intervallo 1D:
$0.2541
$0.2895
Intervallo di 1 settimana:
$0.245
$0.2895
Portata 52W:
$0.217
$1.74
In 8 Bio Inc Stock (INAB) Company Profile
Nome
In 8 Bio Inc
Settore
Industria
Telefono
(646) 600-6438
Indirizzo
EMPIRE STATE BUILDING, NEW YORK
Confronta INAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
0.26 | 19.57M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-03-18 | Iniziato | Laidlaw | Buy |
| 2022-08-30 | Iniziato | H.C. Wainwright | Buy |
In 8 Bio Inc Borsa (INAB) Ultime notizie
Canadian North Resources Inc. Expands Metallurgical Programs Applying Low-carbon Footprint Bioleaching Technology on Ferguson Lake Ni-Cu-Co PGE project - Yahoo Canada Finance
Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews
Global Nucleic Acid Amplification Testing Market to Grow Rapidly at an ~8% CAGR by 2032 | DelveInsight - GlobeNewswire
Genetic Medicine Pioneer Passage Bio Sets March Investor Conference Schedule - StockTitan
Title: bluebird bio Announces Positive Phase 1/2 Clinical Trial Data for Gene Therapy - Defense World
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned - Yahoo Finance
What's Going On With Gene Therapy Company Bluebird Bio Stock Today? - Benzinga
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from - GlobeNewswire
Annovis to Host Patients' Live Forum on February 27, 2025 - Quantisnow
Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - The Globe and Mail
IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML - GlobeNewswire Inc.
KALA BIO Announces Chief Executive Officer Transition - GlobeNewswire
INmune Bio Inc. Discloses New Investor and Webinar PresentationsOn February 10, 2025, INmune Bio Inc. (NASDAQ: INMB) submitted an 8-K form to the Securities and Exchange Commission, revealing that the company had developed an Investor Presentati - Defense World
Plug Power (NASDAQ:PLUG) Enters Into Standby Equity Purchase Agreement with YA II PN, LTD - Defense World
Third Harmonic Bio, Inc. Announces Restructuring Plan - TipRanks
Mustang Bio Closes $8 Million Public Offering - citybiz
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis - GlobeNewswire
Mustang Bio Announces Closing of $8 Million Public Offering - The Manila Times
Mustang Bio, Inc. Completes Public Offering, Raising Approximately $8 Million for Cancer Cell Therapy Development - Nasdaq
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) - The Manila Times
Bluebird bio Inc (NASDAQ: BLUE) Now Carries A 12-Month Price Target Of $25. - Marketing Sentinel
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - Quantisnow
Mustang Bio Announces Pricing of $8 Million Public Offering - GlobeNewswire
2seventy bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results - Business Wire
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease - Quantisnow
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering - Quantisnow
Why INmune Bio Inc (INMB) Is Skyrocketing So Far In 2025 - Insider Monkey
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering - Quantisnow
Passage Bio shares transition to Nasdaq Capital Market - Investing.com
Annovis Bio, Inc. Announces Proposed Public Offering - Quantisnow
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress - Yahoo Finance
SAB BIO Announces Positive Topline Phase 1 Clinical Results - GlobeNewswire
Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - GlobeNewswire
Breakeven On The Horizon For Belite Bio, Inc (NASDAQ:BLTE) - Yahoo Finance UK
Cabaletta Bio Discloses Unaudited Cash and Cash Equivalents of $164 Million as of December 31, 2024 - Defense World
Palisade Bio Completes All Five SAD Cohorts and Advances to - GlobeNewswire
Vyant Bio (OTCMKTS:VYNT) Shares Up 7.8% – Time to Buy? - Defense World
Mustang Bio Announces Reverse Stock Split - GlobeNewswire
Passage Bio (NASDAQ:PASG) Announces Restructuring Plan and Financial Update - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Cadenza Bio, Inc. Announces Members of the Women's Health Scientific Advisory Board - Chicago Star Media
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc - GuruFocus.com
Pivot Bio Announces Ryan Degnan as Head of Growth - PR Newswire
Adicet Bio Provides Corporate Update - TradingView
Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones - The Bakersfield Californian
7 Best Biotech Stocks to Buy for 2025 | Investing - U.S News & World Report Money
INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025 - Seeking Alpha
Geode Capital Management LLC Increases Holdings in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat
KALA BIO Announces Private Placement Agreement with Institutional Investors - Defense World
KALA BIO Announces $10,750,000 Private Placement - GlobeNewswire
In 8 Bio Inc Azioni (INAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
6.45%
1.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):